Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives
The effectiveness of immunotherapy in rare breast cancer histologies remains limited, likely due to inadequate patient selection using current biomarkers such as PD-L1 and TMB. Further research must focus on refining predictive biomarkers to better identify patients likely to from immunotherapy and enhance outcomes in these challenging clinical settings.
Authors
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Francesco Pantano (ORCID: https://orcid.org/0000-0002-2894-9686)
- Roberta Scafetta
- Marco Donato (ORCID: https://orcid.org/0000-0001-7126-3543)
Institutions
- Università Campus Bio-Medico (IT)
- University of Milan (IT)
- Campus Bio Medico University Hospital (IT)
- University of Florence (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- Current Opinion in Oncology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1097/cco.0000000000001184
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94